Ubs Asset Management Americas Inc Inhibrx, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $345 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$32.76 - $39.56 $86,388 - $104,319
-2,637 Reduced 8.19%
29,580 $1.03 Million
Q3 2023

Nov 13, 2023
BUY
$15.75 - $26.31 $507,417 - $847,629
32,217 New
32,217 $591,000
Q4 2022

Feb 14, 2023
BUY
$20.18 - $33.33 $355,934 - $587,874
17,638 New
17,638 $434,000
Q2 2022

Aug 12, 2022
BUY
$8.52 - $25.26 $85,881 - $254,620
10,080 New
10,080 $114,000

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $626M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email